. . . . . . . "[Treatment of the KATO-III, OCUM-2M, SNU-16, and HSC-39 gastric cancer cell lines harboring FGFR2 amplification with pazopanib resulted in marked decreases of cell survival with IC50 in ranges of 0.1 to 2.0 ?mol/L, whereas the same treatment of those cell lines without FGFR2 amplification had no growth-inhibitory effects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:12:52+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .